- Preparation method of vimodegil
-
The invention provides a preparation method of vimodegil. 2-chloro-5-nitroacetophenone is used as a raw material; 5-oxo-5-(2-chloro-5-nitrophenyl) n-valeraldehyde is prepared through an addition reaction between 2-chloro-5-nitroacetophenone and acrolein,
- -
-
-
- A [...] synthesis of intermediates method and application
-
The invention relates to a method for synthesizing intermediate [...] and application, which belongs to the field of organic synthesis, in particular to intermediate 2 - (2 - chloro - 5 - nitrophenyl) pyridine (i.e. compound A) preparation process, compri
- -
-
Paragraph 0026; 0027; 0028; 0029; 0030; 0031; 0032
(2019/03/28)
-
- Selective Late-Stage Oxygenation of Sulfides with Ground-State Oxygen by Uranyl Photocatalysis
-
Oxygenation is a fundamental transformation in synthesis. Herein, we describe the selective late-stage oxygenation of sulfur-containing complex molecules with ground-state oxygen under ambient conditions. The high oxidation potential of the active uranyl cation (UO22+) enabled the efficient synthesis of sulfones. The ligand-to-metal charge transfer process (LMCT) from O 2p to U 5f within the O=U=O group, which generates a UV center and an oxygen radical, is assumed to be affected by the solvent and additives, and can be tuned to promote selective sulfoxidation. This tunable strategy enabled the batch synthesis of 32 pharmaceuticals and analogues by late-stage oxygenation in an atom- and step-efficient manner.
- Li, Yiming,Rizvi, S. Aal-e-Ali,Hu, Deqing,Sun, Danwen,Gao, Anhui,Zhou, Yubo,Li, Jia,Jiang, Xuefeng
-
supporting information
p. 13499 - 13506
(2019/08/21)
-
- Synthetic Path To Pharmaceutically Acceptable Vismodegib
-
The present invention relates to a new route of synthesis to obtain pharmaceutically acceptable Vismodegib. In addition, besides the synthesis also suitable pharmaceutical compositions and the use of the compound for the treatment of basal-cell carcinomas
- -
-
-
- Preparation method of vismodegib
-
The invention relates to a preparation method of vismodegib. The preparation method of the vismodegib comprises the following steps: taking 2-chlorine-5-nitroacetophenone as a starting material, performing 1,4-addition reaction on the 2-chlorine-5-nitroac
- -
-
Paragraph 0068-0077
(2017/10/07)
-
- Synthesis method of vismodegib
-
The invention discloses a synthesis method of vismodegib. The method comprises the following reactions: firstly, enabling 2-chloro-5-nitrophenyl boronic acid and 2-bromopyridine to make a coupled reaction to generate an intermediate 2-(2-chloro-5-nitro) phenylpyridine; reducing nitro in the 2-(2-chloro-5-nitro) phenylpyridine to amino so as to obtain 2-(2-chloro-5-amino) phenylpyridine; finally, enabling the 2-(2-chloro-5-amino) phenylpyridine and 2-chloro-4-methyl sulfuryl benzaldehyde to make a catalytic reaction to generate the vismodegib. The synthesis method is low in price of raw materials, easy in raw material obtaining, simple and convenient to operate and less in consumption of a catalyst; the reaction product is high in yield, reaction conditions are mild, and aftertreatment is simple in technology and mainly adopts column separation, so that industrial mass production can be realized.
- -
-
Paragraph 0029; 0030; 0031
(2017/07/19)
-
- Palladium-Catalyzed ortho-Selective C-H Chlorination of Benzamide Derivatives under Anodic Oxidation Conditions
-
The palladium-catalyzed ortho-selective chlorination of N-quinolinylbenzamide derivatives with hydrochloric acid was achieved under anodic oxidation conditions. The use of 5,7-dichloro-8-quinolinyl group as directing group was effective for the selective
- Konishi, Miki,Tsuchida, Kazuya,Sano, Katsuya,Kochi, Takuya,Kakiuchi, Fumitoshi
-
p. 8716 - 8724
(2017/08/23)
-
- Manufacturing Development and Genotoxic Impurity Control Strategy of the Hedgehog Pathway Inhibitor Vismodegib
-
The development work toward the robust and efficient manufacturing process to vismodegib, the active pharmaceutical ingredient (API) in Erivedge, is described. The optimization of the four-stage manufacturing process was designed to produce the API with the required critical quality attributes: (1) the selective catalytic hydrogenation reduction of the nitro compound 3 to the corresponding aniline 4 while minimizing the formation of potential genotoxic (mutagenic) impurities; (2) the control of the polymorphic phase and multipoint specification for particle size distribution.
- Angelaud, Remy,Reynolds, Mark,Venkatramani, Cadapakam,Savage, Scott,Trafelet, Huldreich,Landmesser, Thomas,Demel, Peter,Levis, Michael,Ruha, Olivier,Rueckert, Baerbel,Jaeggi, Heinz
-
supporting information
p. 1509 - 1519
(2016/08/30)
-
- Method for preparing Vismodegib
-
The invention provides a preparation method for vismodegib, and in other words, a preparation method for 2-chloro-N-(4-chloro-3-(pyridin-2-yl)-phenyl)-4-(methylsulfonyl)benzamide. The method comprises: firstly preparing an intermediate 2-(3-nitrophenyl)py
- -
-
-
- Vismodegib and wherein the intermediate preparation method
-
The invention provides a preparation method for vismodegib and an intermediate of vismodegib, in other words, a preparation method for 2-chloro-N-(4-chloro-3-(pyridin-2-yl)-phenyl)-4-(methylsulfonyl)benzamide and the intermediate. The method comprises: ta
- -
-
-
- Meta-Selective CAr-H Nitration of Arenes through a Ru3(CO)12-Catalyzed Ortho-Metalation Strategy
-
The first example of transition metal-catalyzed meta-selective CAr-H nitration of arenes is described. With the use of Ru3(CO)12 as the catalyst and Cu(NO3)2·3H2O as the nitro source, a wide spectrum of arenes bearing diversified N-heterocycles or oximido as the directing groups were nitrated with meta-selectivity exclusively. Mechanism studies have demonstrated the formation of a new 18e-octahedral ruthenium species as a key ortho-CAr-H metalated intermediate, which may be responsible for the subsequent meta-selective electrophilic aromatic substitution (SEAr). Moreover, this approach provides a fast-track strategy for atom/step economical synthesis of many useful pharmaceutical molecules.
- Fan, Zhoulong,Ni, Jiabin,Zhang, Ao
-
p. 8470 - 8475
(2016/07/26)
-
- Click reaction as a tool to combine pharmacophores: The case of Vismodegib
-
Abstract The design and the preparation of a small library of 1,4-diphenyl-1,2,3-triazole derivatives is reported, with the aim to obtain a new class of Hedgehog pathway inhibitors. The smoothened protein is part of the hedgehog signaling pathway that is
- Christodoulou, Michael S.,Mori, Mattia,Pantano, Rebecca,Alfonsi, Romina,Infante, Paola,Botta, Maurizio,Damia, Giovanna,Ricci, Francesca,Sotiropoulou, Panagiota A.,Liekens, Sandra,Botta, Bruno,Passarella, Daniele
-
p. 938 - 943
(2015/06/08)
-
- A facile synthetic route for antineoplastic drug GDC-0449
-
In the current study a facile synthetic route for preparing antineoplastic drug GDC-0449 is investigated. Starting with pyridine-1-oxide and 1-iodo-3-nitrobenzene, the intermediate product 2-(2-chloro-5-nitrophenyl) pyridine was prepared by cross-coupling
- Cao, Meng,Hu, Hua-You,Zhao, Hu-Cheng,Zhang, Xi-Quan,Gu, Hong-Mei,Yang, Ling,Cai, Jin,Wang, Peng,Hu, Bing,Ji, Min
-
p. 1408 - 1414
(2014/07/21)
-
- PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING
-
The invention provides novel inhibitors of hedgehog signaling that are useful as s therapeutic agent for treating malignancies where the compounds have the general formula (I): where A, X, Y R1, R2, R3, R4, m and n are as described herein.
- -
-
Page/Page column 88
(2009/11/29)
-
- GDC-0449-A potent inhibitor of the hedgehog pathway
-
SAR for a wide variety of heterocyclic replacements for a benzimidazole led to the discovery of functionalized 2-pyridyl amides as novel inhibitors of the hedgehog pathway. The 2-pyridyl amides were optimized for potency, PK, and drug-like properties by modifications to the amide portion of the molecule resulting in 31 (GDC-0449). Amide 31 produced complete tumor regression at doses as low as 12.5 mg/kg BID in a medulloblastoma allograft mouse model that is wholly dependent on the Hh pathway for growth and is currently in human clinical trials, where it is initially being evaluated for the treatment of BCC.
- Robarge, Kirk D.,Brunton, Shirley A.,Castanedo, Georgette M.,Cui, Yong,Dina, Michael S.,Goldsmith, Richard,Gould, Stephen E.,Guichert, Oivin,Gunzner, Janet L.,Halladay, Jason,Jia, Wei,Khojasteh, Cyrus,Koehler, Michael F.T.,Kotkow, Karen,La, Hank,LaLonde, Rebecca L.,Lau, Kevin,Lee, Leslie,Marshall, Derek,Marsters Jr., James C.,Murray, Lesley J.,Qian, Changgeng,Rubin, Lee L.,Salphati, Laurent,Stanley, Mark S.,Stibbard, John H.A.,Sutherlin, Daniel P.,Ubhayaker, Savita,Wang, Shumei,Wong, Susan,Xie, Minli
-
scheme or table
p. 5576 - 5581
(2010/04/05)
-
- Pyridyl inhibitors of hedgehog signalling
-
The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
- -
-
Page/Page column 74
(2010/10/20)
-